Noramco Cannabinoids Business to Become Purisys
Noramco announced today that its industry-leading cannabinoids business will become a separate company – Purisys, LLC.
Noramco Presents Comments and Answers Questions at FDA Hearing on Cannabidiol
Noramco presented testimony and answered questions at the Food and Drug Administration’s (FDA) Scientific Data and Information about Products Containing Cannabis or Cannabis-Derived Compounds, Part 15 Public Hearing.
Noramco and Willow Biosciences Announce Joint Development of Biosynthesis Platform for Cannabidiol
Noramco and Willow Biosciences Inc. today announced they have entered into an exclusive Joint Development Agreement (“JDA”) to collaboratively develop a yeast-based biosynthesis platform for the production and distribution of cannabidiol.
Nemus Bioscience Signs Agreement with Noramco
Nemus Bioscience announced an agreement with Noramco for the manufacturing and scale-up of proprietary analog of cannabidiol (CBD) licensed from the University of Mississippi.
Noramco Adds Capacity and Dual Sources of Supply for Cannabinoids
Noramco, a leader in controlled substances and cannabinoids, is adding commercial-scale capacity of dronabinol (THC) at its Athens, Georgia, United States facility. The expansion comes in response to rising demand for its highly pure cannabidiol (CBD) and dronabinol (THC) analogs of cannabis sativa.
Noramco Announces Provisional Patent Application of Proprietary Cannabidiol (CBD)
Noramco, a global leading producer of controlled substances, including cannabinoids for the pharmaceutical industry, today announced that it has filed a provisional patent application with the US Patent and Trademark Office (USPTO) directed to its proprietary pure cannabidiol (CBD) compositions.
- 1
- 2
Noramco welcomes enquiries from the news media.
Whether you are looking for basic company information or have a follow up question regarding a recent press release, we are here to help. During regular business hours (8:00AM-5:30PM EST, M-F) members of the media should call our corporate headquarters.
A major producer of specialty APIs for the pharmaceutical industry, Noramco is qualified to provide commentary in a number of topic areas, including API research and development, reference standards, and custom synthesis. For assistance, contact us.